108749-08-2

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE
• Synonyms: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE;2,7-Naphthyridine,1,2,3,4-tetrahydro-(9CI);2,7-Naphthyridine, 1,2,3,4-tetrahydro;1,2,3,4-Tetrahydro-2,7-naphthyridine ,95%
• CAS NO: 108749-08-2
• Molecular Formula: C₈H₁₀N₂
• Molecular Weight: 134.1784
• Product Categories: PYRIDINE
• Mol File: 108749-08-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 248-250 °C(Solv: water (7732-18-5))
• Boiling Point: 244.473 °C at 760 mmHg
• Flash Point: 101.654 °C
• Appearance: /
• Density: 1.069 g/cm³
• Vapor Pressure: 0.0303mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.93±0.20(Predicted)
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE(108749-08-2)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE(108749-08-2)

Safety Data

• Hazardous Substances Data: 108749-08-2(Hazardous Substances Data)

Usage

General Description

1,2,3,4-Tetrahydro-[2,7]naphthyridine is a chemical compound with the molecular formula C11H12N2. It is a heterocyclic compound that contains a ring structure composed of four carbon atoms and two nitrogen atoms. 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE is used in the pharmaceutical industry as a building block for the synthesis of various bioactive molecules and pharmaceutical drugs. It has shown potential as a therapeutic agent for the treatment of various diseases, including cancer and infectious diseases. The compound's structure and properties make it a valuable tool for medicinal chemistry research and drug development.

InChI:InChI=1/C8H10N2/c1-3-9-5-8-6-10-4-2-7(1)8/h1,3,5,10H,2,4,6H2

Upstream product

• 42285-29-0 ethyl 2-(3-cyanopyridin-4-yl)acetate 
• 5444-01-9 3-cyano-4-methylpyridine 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 27224-97-1 1,3,6,8-tetrachloro-2,7-naphthyridine 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 1380064-29-8 2,7-naphthyridine-1,3,6,8(2H,4H,5H,7H)-tetraone 
• 253-45-2 [2,7]naphthyridine 

Downstream Products

• 885270-18-8 tert-butyl octahydro-2,7-naphthyridine-2(1H)-carboxylate 
• 1438084-34-4 tert-butyl 7-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-quinazolin-6-yl)oxy)propyl)octahydro-2,7-naphthyridine-2(1H)-carboxylate 
• 1438073-74-5 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(octahydro-2,7-naphthyridin-2(1H)-yl)propoxy)quinazolin-4-amine 
• 1362159-43-0 C₂₂H₂₁N₃O₃S 

Relevant articles and documents

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.